Quality concerns around Indian pharmaceutical manufacturing surface in the news with some regularity — and each time they do, they add to a broader climate of scrutiny that every brand owner sourcing from India has to navigate, regardless of how solid their own manufacturing partner actually is. Rather than reacting to individual headlines, it’s worth understanding the pattern behind them, and using that understanding to sharpen how you evaluate a manufacturer.
Already evaluating a manufacturer? Pair this with our detailed Quality Control Guide for the full technical breakdown of what a robust QC system actually looks like.
Why This Scrutiny Keeps Intensifying, Not Fading
India manufactures a very large share of the world’s generic medicines. That scale cuts both ways: it’s the foundation of the country’s global pharmaceutical reputation, and it also means quality failures — even when isolated to a small number of manufacturers — draw disproportionate international attention. The consistent regulatory response has been to tighten inspection regimes and GMP enforcement further, not to relax them.
What a Certificate Actually Confirms — and What It Doesn’t
A WHO-GMP certificate is a meaningful, necessary baseline. It confirms a facility passed a formal inspection against a defined set of standards at a specific point in time.
What it doesn’t automatically confirm is the day-to-day discipline of quality operations between inspections — whether raw materials are consistently qualified before use, whether documentation is genuinely complete and accurate, or whether an out-of-specification result actually triggers a real investigation rather than getting quietly reworked.
The Structural Gaps That Actually Cause Failures
Rather than speculating about any specific incident, it’s more useful to understand the underlying risk factors that consistently appear wherever quality failures do occur:
| Risk Factor | What It Looks Like | Why It Matters |
|---|---|---|
| Price-driven raw material sourcing | Choosing the cheapest API/excipient vendor without full qualification | Compromised raw materials are the single most common root cause of quality failure |
| Weak in-process controls | Minimal monitoring during production, relying only on final testing | Problems caught only at the end are far more costly, and some defects can’t be detected after the fact |
| Incomplete documentation | Missing or inconsistent Batch Manufacturing Records | Makes it impossible to trace or investigate a problem when one does occur |
| Limited independent testing capability | Outsourcing critical testing rather than maintaining in-house capability | Slower turnaround and less direct accountability for results |
Your Responsibility Doesn’t End at Signing a Contract
It’s worth being direct about this: outsourcing manufacturing does not outsource legal or reputational responsibility. Under a loan license arrangement, the brand owner holding the drug license remains accountable for every batch sold under their name — which means manufacturer due diligence isn’t a one-time checkbox before signing, it’s an ongoing responsibility.
View manufacturing details for paracetamol-suspension-manufacturing
A Practical Due Diligence Checklist
Beyond asking to see a WHO-GMP certificate, ask for the following directly:
- ☐ Their Approved Vendor List and raw material qualification process
- ☐ A sample Certificate of Analysis and Batch Manufacturing Record
- ☐ How they handle an Out-of-Specification (OOS) result — is there a documented investigation process?
- ☐ What system they use for electronic data capture and audit trails
- ☐ Whether they welcome an independent facility audit from you or a third party
How Saar Biotech Approaches This
We treat every one of the questions above as things a prospective partner should be able to ask us directly — not information we hold back. Our full raw material qualification process, documentation practices, and OOS investigation procedure are detailed in our Quality Control Guide, and we welcome facility audits from partner brands as a standard part of how we build trust.
Conclusion
Headlines about pharma quality concerns will keep surfacing — they’re a function of India’s scale in global generic manufacturing, and the regulatory response continues to tighten rather than ease. The right response as a brand owner isn’t to be anxious about the industry generally; it’s to know exactly what separates a manufacturer with real, verifiable quality discipline from one that’s merely certified. Ask the specific questions. Insist on specific answers.
Want to see exactly how our quality systems work, in detail?